How does the 'Batch-of-One' model change the PAT landscape? Personalized medicines, such as CAR-T therapies, represent a paradigm shift: the patient is the batch. In this scenario, there is no room for error, and no material to waste on traditional testing. PAT tools must be non-destructive and capable of monitoring very small volumes. The ability to monitor cell viability and phenotype in...